The Food and Drug Administration’s recent approval of new treatment options for patients suffering from conditions such as cancer, rheumatoid arthritis and ulcerative colitis is the latest recognition of a nascent prescription drug sector known as biosimilars. The FDA’s actions are critical for promoting a vibrant U.S. marketplace for biosimilars, which have the potential to reduce costs in our health care system and increase access to care for millions of patients.
Biosimilar drugs offer promise for US health care system
